Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a progressive condition characterized by high blood pressure in the arteries of the lungs, leading to shortness of breath, fatigue, and chest pain. Over time, this increased pressure can cause the heart to work harder, resulting in heart failure and other complications.

Recent advances in understanding the molecular pathways involved in PAH have driven the development of more targeted therapies aimed at reducing pulmonary vascular resistance and slowing disease progression. These therapies focus not only on managing symptoms but also on addressing the underlying causes of increased blood pressure in the lungs.

iNGENū’s team of researchers and clinicians is committed to advancing PAH research. Through innovative trial designs and a patient-focused approach, we strive to accelerate the development of new treatments that have the potential to enhance the quality of life for individuals living with pulmonary arterial hypertension.

Women are

3x

more likely to develop PAH

 

 

40%

of patients with untreated PAH develop right heart failure

 

 

10%

of PAH cases are heritable, often involving mutations in the BMPR2 gene.





Our clinical team has over

120

years of combined clinical trial experience

Download Our Paper

Fill out this form to download our white paper on how to overcome the biggest obstacles in conducting a Pulmonary Arterial Hypertension Clinical Trial.

iNGENu CRO - Pulmonary Arterial Hypertension Clinical Trials

In light of the impact Pulmonary Arterial Hypertension has on individuals and society as a whole, continued research efforts are crucial to improve diagnosis, treatment, and ultimately, patients' quality of life.

The development of clinical trial protocols that meet FDA approval standards is crucial for the success of new Pulmonary Arterial Hypertension treatments.